​​LOTIS-9: Loncastuximab tesirine and rituximab in unfit/frail patients with DLBCL
11 months ago
[{"url":"https://i.ytimg.com/vi/vSvCDNvNe_I/hq720.jpg?sqp=-oaymwEcCOgCEMoBSFXyq4qpAw4IARUAAIhCGAFwAcABBg==&rs=AOn4CLDTROlYlXB1pQ-LtNnBZJbkhhIYZg","width":360,"height":202},{"url":"https://i.ytimg.com/vi/vSvCDNvNe_I/hq720.jpg?sqp=-oaymwEcCNAFEJQDSFXyq4qpAw4IARUAAIhCGAFwAcABBg==&rs=AOn4CLCh0gra9gc9icABbaTkq4kE_cEBHw","width":720,"height":404}]
{"url":"https://i.ytimg.com/an_webp/vSvCDNvNe_I/mqdefault_6s.webp?du=3000&sqp=CNbOsakG&rs=AOn4CLCXB2Oow5dQhpV5hrRkwodN1EsztQ","width":320,"height":180}
[{"text":"Jason Westin, MD, FACP, The University of Texas MD Anderson Cancer Center, Houston, TX, briefly shares some insights into the\u00a0..."}]
{"name":"VJHemOnc \u2013 Video Journal of Hematological Oncology","id":"UCsQXL4_zTA-FoG9RA1tEGiw","thumbnails":[{"url":"https://yt3.ggpht.com/tLfkaYbACnFuAto-jU_XMyorvysy280aW3Kj1oDAKOH7nd58XYlz5rEL24x9ScNjruMr2YYw9w=s68-c-k-c0x00ffffff-no-rj","width":68,"height":68}],"link":"https://www.youtube.com/channel/UCsQXL4_zTA-FoG9RA1tEGiw"}
{"title":"\u200b\u200bLOTIS-9: Loncastuximab tesirine and rituximab in unfit/frail patients with DLBCL by VJHemOnc \u2013 Video Journal of Hematological Oncology 163 views 11 months ago 1 minute, 29 seconds","duration":"1 minute, 29 seconds"}